Archive: July 1, 2026

UST Named Among World’s Most Ethical Companies in 2026 by Ethisphere

Business Wire India

UST, a leading AI and technology transformation solutions company, has been recognized as one of the World’s Most Ethical Companies® by Ethisphere. UST is one of just six software companies worldwide to be recognized by Ethisphere in 2026 and is the only privately held software company on the exclusive elite list, a reflection of the company’s deeply held commitment to ethical practices.

This recognition honors organizations that exemplify ethical business conduct by implementing comprehensive programs which generate positive outcomes for employees, communities, and stakeholders while also fostering sustainable, long-term business growth. UST was commended by Ethisphere for demonstrating that it has policies in place to foster a strong culture of ethics based on integrity, ethical governance, and responsible business practices.

UST’s inclusion on this elite list underscores the company’s commitment to integrating ethics and integrity into every aspect of its business practices. By prioritizing trust, transparency, and accountability, UST ensures that all its solutions deliver measurable value and meaningful impact for clients, employees, and stakeholders.

To compile its rankings, Ethisphere engages in a rigorous assessment of all applicants based on its Ethisphere Ethics Quotient®. Applicants are evaluated using more than 240 data points across a number of categories including culture, ESG, compliance, and governance. This data undergoes further qualitative analysis by Ethisphere’s panel of experts. In 2026, 138 companies from 17 countries were recognized by Ethisphere.

“We are honored to be named one of the World’s Most Ethical Companies as this distinction speaks to the strength of UST’s people, culture, and values. This recognition underscores the effectiveness of our efforts to empower employees to responsibly bridge technology and AI innovation while driving real outcomes for our clients. Trust, transparency, and accountability are foundational to our work, and we remain dedicated to setting the benchmark for excellence in ethical governance as we create lasting value for our employees, clients, stakeholders, and communities worldwide,” said Colleen Doherty, Chief People Officer, UST.

“This recognition from Ethisphere highlights UST’s strong commitment to governance, ethics, and integrity as core drivers of sustainable growth, going well beyond compliance to embed these principles across all aspects of our business. Notably, UST has voluntarily benchmarked itself against global public companies and stands as the only private software company worldwide to receive this honor, reflecting the strength of our governance framework and ethical standards. Trust remains central to everything we do—from client delivery to leadership decisions—and this achievement is a testament to every UST employee who consistently demonstrates accountability, integrity, and continuous improvement,” said Ramanathan Raghunathan, Vice President & Global Head of Governance, Risk, and Compliance, UST.

“Congratulations to UST for achieving recognition as one of the World’s Most Ethical Companies®. As we mark the 20th class of honorees, this group continues to raise the bar for business integrity by embedding ethics into everyday decision-making and long-term strategy. UST’s recognition as the only private software company among this year’s honorees highlights the strength of its commitment to ethics, compliance, and governance as drivers of long-term performance,” said Erica Salmon Byrne, Chief Strategy Officer and Executive Chair, Ethisphere.

Galderma Provides Progress Update Regarding RelabotulinumtoxinA Regulatory Submission in the United States

Business Wire India

• Galderma received a Complete Response Letter from the FDA with comments related to observations during manufacturing site inspection and analytical method optimization
• Relfydess is approved in 33 markets and already launched in more than 20, including across Europe, the Middle East and Australia, with an encouraging early launch trajectory supported by positive healthcare professional feedback
• Regulatory filings in other territories are ongoing and remain on track

Ad hoc announcement pursuant to Art. 53 LR

Galderma (SIX: GALD) today provided progress updates regarding the regulatory review of its pending Biologics License Application (“BLA”) for RelabotulinumtoxinA with the U.S. Food and Drug Administration (“FDA”). The Company has received a Complete Response Letter (CRL) from the FDA with comments related to observations during manufacturing site inspection and analytical method optimization. As part of its review, the FDA conducted a Pre-License Inspection (PLI) of Galderma’s manufacturing site. All other aspects of the BLA, including safety- and efficacy-related parts, did not solicit deficiencies to be addressed.

The FDA made observations during the PLI for which Galderma is putting in place corrective and preventive actions. Galderma will also be seeking further guidance through continued open dialogue with the FDA toward resolution of the relevant observations. Galderma plans to rapidly respond to the CRL and advancing RelabotulinumtoxinA in the U.S. remains a top priority.

The observations do not impact approvals, launches, or regulatory reviews in other International markets.

Global launches progressing on track

As of today, Relfydess is approved in 33 markets and already launched in more than 20, including in Europe, the United Kingdom, the Middle East, Asia, and Australia, with an encouraging early launch trajectory supported by positive healthcare professional feedback. Since 2022, this Galderma manufacturing site has completed 10 inspections from key regulatory authorities from around the world serving as the basis for International Relfydess launches. Regulatory filings in other territories are ongoing and remain on track.

Building a dermatology powerhouse

Galderma remains on a clear path to become the world’s undisputed dermatology powerhouse spanning the full spectrum of fast-growing markets across Injectable Aesthetics, Dermatological Skincare and Therapeutic Dermatology.

In Injectable Aesthetics, Galderma is firmly positioned on a trajectory to global leadership – not only in sales and market share, but also in innovation – supported by fully integrated in-house capabilities across discovery, research, development, manufacturing and commercialization of best-in-class products.

We will continue to build on this momentum through our robust pipeline, expanding the number of early-stage assets under development. Galderma leads the industry in the number of active aesthetic development programs, further reinforcing its leadership position in the U.S. and globally.

Galderma has the largest and most innovative Injectable Aesthetic portfolio on the market. Given our strong market position, we believe we are exceptionally well placed to capitalize on opportunities in this fast-growing market.

About Relfydess(relabotulinumtoxinA)
Pioneered by Galderma, Relfydess is the first and only ready-to-use liquid neuromodulator created with PEARL Technology that is designed to preserve molecule integrity.PEARL Technology is designed to deliver a highly active, innovative, complex-free molecule, creating a product that enables up to 39% of patients seeing effects from day one and up to 75% of patients maintaining improvements for six months. Relfydess is optimized for simple volumetric dosing, without reconstitution, to increase ease-of-use and help ensure consistent dose/volume every time.

About Galderma
Galderma (SIX: GALD) is the pure-play dermatology category leader, present in approximately 90 countries. We deliver an innovative, science-based portfolio of premium flagship brands and services that span the full spectrum of the fast-growing dermatology market through Injectable Aesthetics, Dermatological Skincare and Therapeutic Dermatology. Since our foundation in 1981, we have dedicated our focus and passion to the human body’s largest organ – the skin – meeting individual consumer and patient needs with superior outcomes in partnership with healthcare professionals. Because we understand that the skin we are in shapes our lives, we are advancing dermatology for every skin story. For more information: www.galderma.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260630345734/en/

Archer® Proves Purpose-Built AI Beats General-Purpose LLMs on Regulatory Change Management: 95% Verified Accuracy, 80x Faster, 92% Lower Cost

Business Wire India

For enterprises deploying AI in compliance, a wrong date is a missed deadline. The more dangerous failure is a wrong answer the model returns with high confidence, one that flows silently into a compliance calendar and is only discovered after the window has passed. Archer^® today released results showing purpose-built AI beats a general-purpose large language model (LLM) on regulatory work, and it’s not close. This head-to-head test compared Archer’s purpose-built, vertical-specific AI and proprietary data sets against a leading general-purpose LLM, on a core compliance task: determining the publication, effective and comment-close dates of regulatory documents across six jurisdictions.

General-purpose models are a genuine breakthrough, and this is no referendum on their quality. The question Archer set out to answer is narrower and more practical: what it takes to make a specific, high-stakes determination reliable, fast and affordable at scale. A vertical, domain-focused process, grounded in an expert-verified knowledge base, wins on all three at once.

Accuracy: 90% fewer wrong answers

On the same 55 documents, the general-purpose LLM was wrong 56% of the time. Confidence made it worse, not better. Of the answers it rated high confidence, 35% were still wrong. With Archer Evolv, more than 95% of determinations are verified outright, and the rest are routed to an expert before use. Not a single wrong date reached production. Nothing ships unverified.

A model’s own confidence is not a control. Of the answers the general purpose LLM rated high confidence, 35% were wrong. That accuracy gap is the precondition for deploying agentic AI responsibly, because an autonomous operator is only as trustworthy as the determinations beneath it. Verified, source-traceable, expert-governed answers make it possible to safely deploy AI agents across an enterprise. This is the core of AI governance, and the layer Archer is built to provide.

“In compliance, an answer that is fast and cheap, but wrong, is worthless, and an answer you cannot trace is a liability,” said Kayvan Alikhani, Chief Product and Technology Officer of Archer. “Archer’s purpose-built AI verified more than 95% of determinations in real time. That is the foundation that lets enterprises scale AI agents without losing control of the outcome.”

Speed: verified answers in real time

Per request, the general-purpose process averaged about four seconds per response within a five-second timeout. Archer Evolv served a verified date in roughly five-hundredths of a second, about 80 times faster on repeat lookups. For AI agents and analysts working at the pace of a regulatory calendar, that is the difference between keeping up and becoming the bottleneck.

Cost: a persistent, verified knowledge base, not on-demand inference

A general-purpose process recomputes the answer on every request, with no memory of what it found before. Archer Evolv computes once at ingestion, verifies the result into a scalable, expert-governed knowledge base, and persists it for every future lookup at a fraction of the cost and latency. When a regulation is amended, Evolv catches the change proactively, re-verifies, and versions the updated answer. Nothing served is ever stale. For a 500-document corpus with 12 lookups each per month, that is 6,000 determinations against only 500. Archer Evolv avoids roughly 92% of the inference calls, a structural saving that widens as volume grows.

Context is what makes this possible

Archer Evolv’s advantage traces to context: before any AI runs, it assesses the organization’s jurisdictions, products, business units, risks and regulatory themes, so every determination is grounded in what is relevant to that enterprise. This is the difference between an answer and a defensible answer. The more agents a company deploys, the more valuable that foundation becomes, because every agent inherits the same verified, source-traceable grounding rather than re-deriving the world from scratch.

“The companies that win the next decade of SaaS will pair domain-specific AI with proprietary, vertical-specific context the foundation models cannot replicate,” said Bill Diaz, Chief Executive Officer of Archer. “That is the moat, and it compounds. This test is the proof.”

The full methodology, source data and case study are available on Archer’s thought leadership website, compliance.ai/evolv_assets/case-01-evolv-vs-raw-llm.html. To see Archer Evolv in action, visit www.archerirm.com.

About Archer

Archer powers how the world’s leading enterprises govern risk, compliance, and regulatory change. More than 1,300 organizations run on Archer, including half the Fortune 500 and 37 of the top 50 global banks. A new regulatory change lands somewhere in the world every six minutes, and agentic AI is outpacing most teams’ ability to govern it. Archer’s purpose-built AI is grounded in the deepest regulatory data and domain expertise in GRC, so every result traces back to its source, and every decision can be defended. Archer delivers solutions across the full range of GRC, including regulatory change management, AI risk management, regulatory intelligence, third-party risk, and IT and security risk. Learn more at www.archerirm.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260630423261/en/